Serum soluble RAGE level inversely correlates with left ventricular hypertrophy in essential hypertension patients

Q, Liu; Hb, Chen; Luo, Min; Zheng, Huan

doi:10.4238/gmr.15028414

Cited by 14 publications

(10 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Systolic pressure increases, while diastolic pressure increases till the age of 50 years after which diastolic pressure decreases. 50 Systolic HTN affects more than 50% individuals older than 60 years of age. Isolated systolic HTN is most common type of HTN among the elderly individuals.…”

Section: Interaction Of Ages With Rage Resulting In Changes In Vasculmentioning

confidence: 99%

Do Advanced Glycation End Products and Its Receptor Play a Role in Pathophysiology of Hypertension?

Prasad

Mishra

2017

Int J Angiol

View full text Add to dashboard Cite

Hypertension (HTN) accounts for 6% of death worldwide. The prevalence of HTN varies being lowest in rural India (3.4% in men and 6.8% in women), and highest in Poland (68.9% in men and 72.5% in women).1 Prevalence of HTN was 27.1% in men and 30.1% in women in the adult population of United States. 1HTN is a risk factor for cardiovascular diseases including stroke and myocardial infarction. There are two types of HTN. Primary or essential which accounts for 90 to 95% and its etiology is not known. Secondary HTN which accounts for 5 to 10% and its etiology is known.Advanced glycation end products (AGEs) and its cellular receptor (RAGE) may play a role in the pathophysiology of HTN. Interaction of AGEs with RAGE increases the expression and release of inflammatory cytokines, generation of reactive oxygen species (ROS), and activates nuclear factor kappa-B (NF-κB).2-4 These agents might affect the structures of arterial wall and/or produce contraction of the arterial wall. Various measures are available for the prevention and treatment of HTN. 5 However, very little attention has been given to the role of AGEs and its receptors in initiation and maintenance of arterial stiffness and HTN. Keywords► advanced glycation end products ► receptor for AGE ► soluble receptor for AGE ► hypertension ► arterial stiffness ► management of hypertension AbstractThere is a close relationship between arterial stiffness and blood pressure. The studies suggest that the advanced glycation end products (AGEs) and its cell receptor (RAGE) are involved in the arterial stiffness in two ways: changes in arterial structure and vascular function. Plasma levels of AGEs and expression of RAGE are elevated, while the levels of soluble RAGE (sRAGE) and endogenous secretory RAGE (esRAGE) are lowered in patients with hypertension (HTN). There is a positive correlation between plasma levels of AGEs and arterial stiffness, and an inverse association between arterial stiffness/HTN, and serum levels of sRAGE and esRAGE. Various measures can reduce the levels of AGEs and expression of RAGE, and elevate sRAGE. Arterial stiffness and blood pressure could be reduced by lowering the serum levels of AGEs, and increasing the levels of sRAGE. Levels of AGEs can be lowered by reducing the consumption of AGE-rich diet, short duration of cooking in moist heat at low temperature, and cessation of cigarette smoking. Drugs such as aminoguanidine, vitamins, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-II receptor blockers, statins, and metformin inhibit AGE formation. Alagebrium, an AGE breakers reduces levels of AGEs. Clinical trials with some drugs tend to reduce stiffness. Systemic administration of sRAGE has beneficial effect in animal studies. In conclusion, AGE-RAGE axis is involved in arterial stiffness and HTN. The studies suggest that inhibition of AGEs formation, reduction of AGE consumption, blockade of AGE-RAGE interaction, suppression of RAGE expression, and exogenous administration of sRAGE may be novel therapeutic strategies for treatment...

show abstract

Section: Interaction Of Ages With Rage Resulting In Changes In Vasculmentioning

confidence: 99%

Do Advanced Glycation End Products and Its Receptor Play a Role in Pathophysiology of Hypertension?

Prasad

Mishra

2017

Int J Angiol

View full text Add to dashboard Cite

show abstract

“…Previously, sRAGE decreased plasma levels were described in a population of hypertensive patients including severe stages of hypertension [5] and left ventricular hypertrophy (indexed for body surface area) correlated inversely with sRAGE in a group of long-lasting treated hypertensive disease [18]. As confounding factors, the latter study included older patients among the 81 presenting with left ventricular hypertrophy and a large percentage of patients with coronary artery disease [25].…”

Section: Discussionmentioning

confidence: 99%

sRAGE and early signs of cardiac target organ damage in mild hypertensives

Maresca

Guasti

Beigrezaei

et al. 2019

Cardiovasc Diabetol

View full text Add to dashboard Cite

BackgroundSoluble Receptor for Advanced Glycation End Products (sRAGE) may be considered a marker inversely related to inflammation and its participation has been established in patients with advanced atherosclerotic vascular diseases. However, it is still unknown whether sRAGE reduction could be early metabolic change in the first stage of hypertension and initial hypertension-associated cardiac damage. We sought to determine the sRAGE values in otherwise healthy, untreated and recently diagnosed mild hypertensives and evaluate their association with blood pressure (BP) values, metabolic parameters, and with subclinical initial signs of cardiac target organ damage (TOD).MethodssRAGE were measured in 100 hypertensive and 100 normotensive subjects matched for age, gender and body mass index (BMI), submitted to a clinic visit and both ambulatory BP monitoring and echocardiography to determine the presence of initial cardiac TOD (presence of signs of left ventricular hypertrophy: left ventricular mass indexed for height2.7 (LVMi) > 48 g/m2.7 for men and > 44 g/m2.7 for women and/or increased left atrial volume 4-chamber indexed for body surface area (LAVi) > 34 ml/m2).ResultssRAGE levels were similar between hypertensive and normotensive subjects and were not significantly correlated with office and 24-h BPs values. However, when subgrouping the hypertensive patients in Hyp-TOD and Hyp-withoutTOD, sRAGE was found to be different among the three groups (p = 0.030), being lower in the Hyp-TOD group than the values of both Hyp-withoutTOD (p = 0.038) and normotensives (p = 0.038). In hypertensive patients sRAGE was negatively related with both LVMi (r = − 0.239, p = 0.034) and LAVi (r = − 0.315, p = 0.005) and was independently related to cardiac TOD also in multivariable analysis.ConclusionsIn this population of mild hypertensives, low circulating sRAGE may be a very early marker of initial TOD, suggesting the possible participation of oxidative stress in initial cardiac changes in human hypertension.Electronic supplementary materialThe online version of this article (10.1186/s12933-019-0821-5) contains supplementary material, which is available to authorized users.

show abstract

“…Cross-sectional studies on human population have suggested circulating sRAGE as potential biomarker of several pathologies although with conflicting data regarding diabetes and cardiovascular diseases [29–32]. Decreased levels of circulating sRAGE or esRAGE have been reported in patients with hypertension [33], metabolic syndrome (MS) [34], in the early phase of type 2 diabetes [35,36] and obesity suggesting sRAGE as an early predictor of cardiovascular risk. Interestingly, sRAGE levels seems to be related to body composition.…”

Section: Introductionmentioning

confidence: 99%

Modulation of soluble receptor for advanced glycation end-products (RAGE) isoforms and their ligands in healthy aging

Scavello

Zeni

Tedesco

et al. 2019

Aging

View full text Add to dashboard Cite

The receptor for advanced glycation end-products (RAGE) recognizes several ligands involved in inflammatory diseases. Two circulating soluble isoforms exist: esRAGE derived from alternative splicing and cRAGE generated by the membrane-bound RAGE (FL-RAGE) proteolysis. Together, esRAGE and cRAGE constitute sRAGE and function as decoy receptors preventing FL-RAGE/ligands binding. We determined serum concentration of both, esRAGE and cRAGE, and their ligands AGEs, HMGB1 and S100A8/A9 in a healthy population of 169 subjects aged 20-90 years. cRAGE showed a negative (r=-0.375, P<0.0001) while AGEs (r=0.160, P=0.0384) and S100A8/A9 (r=0.207, P=0.0091) a positive correlation with age. esRAGE did not change during aging and inversely correlated with Hemoglobin, ALT, insulin, HOMA index, Waist-Hip ratio (W/H), Waist Circumference (WC) and positively with AGEs. cRAGE exhibited also an inverse correlation with WC, W/H, PAI-1, HMGB1, AGEs and S100A8/A9. Age, W/H, HMGB1, S100A8/A9 and AGEs are independent predictors of cRAGE, whereas W/H and AGEs associate with esRAGE. Treatment of cells with glycated albumin reduced cRAGE production and upregulated FL-RAGE. These results indicate that in a healthy population cRAGE is a biomarker of aging while esRAGE represents a more reliable marker of obesity and insulin resistance. Hence, sRAGE isoforms levels could be differentially associated with age-related diseases risk factors.

show abstract

Serum soluble RAGE level inversely correlates with left ventricular hypertrophy in essential hypertension patients

Cited by 14 publications

References 25 publications

Do Advanced Glycation End Products and Its Receptor Play a Role in Pathophysiology of Hypertension?

Do Advanced Glycation End Products and Its Receptor Play a Role in Pathophysiology of Hypertension?

sRAGE and early signs of cardiac target organ damage in mild hypertensives

Modulation of soluble receptor for advanced glycation end-products (RAGE) isoforms and their ligands in healthy aging

Contact Info

Product

Resources

About